Brainstorm Cell Therapeutics Inc. (BCLI)
| Market Cap | 154.30M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -31.81M |
| Shares Out | 29.85M |
| EPS (ttm) | -1.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 24 |
| Last Price | $4.24 |
| Previous Close | $4.21 |
| Change ($) | 0.03 |
| Change (%) | 0.71% |
| Day's Open | 4.28 |
| Day's Range | 4.23 - 4.51 |
| Day's Volume | 956,882 |
| 52-Week Range | 3.80 - 17.95 |
NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm...
The FDA's initial review concluded that current data from BrainStorm Cell Therapeutics Inc's (NASDAQ: BCLI) NurOwn Phase 3 trial in amyotrophic lateral sclerosis (ALS) does not sufficiently pr...
NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that ...
Infinity Pharmaceuticals (NASDAQ: INFI) shares are trading higher Friday after JPMorgan upgraded the stock from Underweight to Neutral. Infinity Pharmaceuticals is a clinical-stage biopharmace...
The company isn't giving up on a promising pipeline drug.
NEW YORK, Feb. 4, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial res...
NEW YORK, Jan. 20, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the p...
NEW YORK, Dec. 28, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the followin...
NEW YORK, Dec. 18, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that ...
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our i...
NEW YORK, Nov. 23, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that ...
Brainstorm Cell Therapeutics (BCLI) news for Tuesday has BCLI stock taking a beating following results from its ALS study. The post Brainstorm Cell Therapeutics News: 8 Things for BCLI Stock I...
The company reported disappointing results from a pivotal clinical trial.
NEW YORK, Nov. 17, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topli...
PHILADELPHIA and NEW YORK, Oct. 26, 2020 /PRNewswire/ -- Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a lea...
Brainstorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q3 2020 Results - Earnings Call Transcript
BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update
NEW YORK, Oct. 15, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial re...
NEW YORK, Oct. 12, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Stacy...
NEW YORK, Oct. 2, 2020 /PRNewswire/ -- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerati...
NEW YORK, Sept. 30, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced the presen...
NEW YORK, Sept. 16, 2020 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc.
Company plans to further strengthen its regulatory expertise and capabilities as ALS phase 3 clinical trial nears completion in Q4 Company plans to further strengthen its regulatory expertise ...
NEW YORK, Aug. 25, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.
NEW YORK, Aug. 19, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.
NEW YORK, Aug. 10, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc (BCLI) CEO Chaim Lebovits on Q2 2020 Results - Earnings Call Transcript
Intratracheal administration of exosomes extracted from MSC’s using NurOwn® technology resulted in statistically significant improvement in multiple lung parameters in a mouse model
NEW YORK, July 8, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, is hosting a Key Opini...
NEW YORK, July 2, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that f...
NEW YORK, June 24, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced a new...
NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced...
NEW YORK, June 11, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Chaim...
WASHINGTON, June 9, 2020 /PRNewswire/ -- The ALS Association and I AM ALS announced today that the organizations have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics (NASD...
NEW YORK, June 3, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Dr. Ra...
NEW YORK, June 2, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today an upd...
NEW YORK, May 27, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that S...
BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q1 2020 Results - Earnings Call Transcript
NEW YORK, N.Y., and TEL AVIV, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leading developer of adult stem cell therapies for neurodegenerat...
NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leading developer of adult stem cell technologies for neurodegenerative diseases, today annou...
NEW YORK and PETACH TIKVAH, Israel, April 03, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenera...
Prof. Frenkel, Chairman of the Group of Thirty (G-30) Board of Trustees, Former Chairman of JPMorgan Chase International and Former Governor of the Bank of Israel Joins the Board to Support th...
NEW YORK, March 06, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. , ( NASDAQ: BCLI ), a leading developer of cell technologies for neurodegenerative diseases, today announced t...
NEW YORK and BOSTON, Feb. 27, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc . ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debili...
BrainStorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q4 2019 Results - Earnings Call Transcript
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc ., (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announ...
NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc . ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today an...
NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that ...
NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapeutics for neurodegenerative diseases, today issued a Lett...
NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitat...
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurod...
About BCLI
Brainstorm Cell Therapeutics, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is devel... [Read more...]
| Industry Biotechnology | Founded 2000 |
| CEO Chaim Lebovits | Employees 40 |
| Stock Exchange NASDAQ | Ticker Symbol BCLI |
Analyst Forecasts
According to one analyst, the rating for BCLI stock is "Hold" and the 12-month stock price forecast is 17.50.